AstraZeneca Gets CDSCO Panel nod to study Anti-cancer Drug Datopotamab Deruxtecan and Durvalumab Dr. Divya Colin23 Feb 2024 6:00 PM ISTNew Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee SEC functional under the Central Drug Standard Control...
AstraZeneca Gets CDSCO Panel Nod to Study anti-cancer drug Dato-DXd and Durvalumab Dr. Divya Colin5 Jan 2024 6:00 PM ISTNew Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Durvalumab safely improves survival in lung cancer patients with limited physical function Dr. Kamal Kant Kohli1 Dec 2023 9:00 AM ISTUSA: A recent study published in eClinicalMedicine has shown single-agent durvalumab to be safe and well tolerated in the first-line treatment of...
AstraZeneca Imfinzi plus chemotherapy approved in China for locally advanced or metastatic biliary tract cancer Ruchika Sharma19 Nov 2023 11:45 AM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
CDSCO nod to AstraZeneca cancer drug Tremelimumab Ruchika Sharma2 Jun 2023 11:53 AM ISTThe approval paves the way for the launch of Tremelimumab solution of 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single-dose vials) in...
AstraZeneca announces positive results from ovarian cancer combo therapy trial Ruchika Sharma7 April 2023 11:30 AM ISTThe safety and tolerability of these combinations are broadly consistent with that observed in prior clinical trials and the known profiles of the...
All SAEs including death should be reported: CDSCO Panel tells AstraZeneca about Durvalumab Dr. Divya Colin25 March 2023 6:00 PM ISTNew Delhi: Granting the protocol amendment proposal presented by drug major AstraZeneca for anticancer drug Durvalumab, the Subject Expert Committee...
Imfinzi plus Imjudo approved in EU for patients with advanced liver and non small cell lung cancers: AstraZeneca Ruchika Sharma25 Feb 2023 10:00 AM ISTUK: AstraZeneca has announced that Imfinzi (durvalumab) and Imjudo (tremelimumab) immunotherapy combinations have been approved in the European Union...
AstraZeneca India gets CDSCO nod for Durvalumab to treat biliary tract cancer Ruchika Sharma17 Feb 2023 12:00 PM ISTNew Delhi: Science-led biopharmaceutical company, AstraZeneca India, has announced additional indication approval from Central Drugs...
AstraZeneca gets Japanese approval for Imfinzi, Imjudo to treat 3 types of cancer Ruchika Sharma28 Dec 2022 11:30 AM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
Setback to AstraZeneca: Imfinzi fails as monotherapy for non-small lung cancer Ruchika Sharma20 Dec 2022 1:30 PM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
AstraZeneca Imfinzi plus chemotherapy recommended for marketing authorisation in EU for advanced biliary tract cancer Ruchika Sharma15 Nov 2022 5:44 PM ISTUK: AstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult...
